Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi (2nd L) speaks at a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi speaks at a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- The headquarters of Kobayashi Pharmaceutical is seen in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi attends a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

JAPAN-OSAKA-HEALTH-KOBAYASHI PHARMACEUTICAL-DIETARY SUPPLEMENTS-DEATH TOLL

(240329) -- OSAKA, March 29, 2024 (Xinhua) -- President of Kobayashi Pharmaceutical Akihiro Kobayashi (2nd L) and others bow at a press conference in the city of Osaka, Japan, March 29, 2024. Japanese drugmaker Kobayashi Pharmaceutical on Friday confirmed a fifth death related to its dietary supplements with red yeast rice, or beni-koji, produced by the company. (Xinhua/Zhang Xiaoyu)

E

2 die, 100 hospitalized after consuming Japan drugmaker's supplements

OSAKA,Japan, March 27 Kyodo - Two people are believed to have died and over 100 hospitalized after consuming red yeast rice dietary supplements from Kobayashi Pharmaceutical Co., the Japanese drugmaker and the health ministry said Tuesday, amid swelling safety concerns over the products.(Kyodo)

E

Japanese drugmaker sees opportunities at China import expo

STORY: Japanese drugmaker sees opportunities at China import expo SHOOTING TIME: Nov. 9, 2023 DATELINE: Nov. 10, 2023 LENGTH: 00:00:49 LOCATION: SHANGHAI, China CATEGORY: ECONOMY SHOTLIST: 1. various of Takeda's exhibits at the sixth CIIE 2. SOUNDBITE (Chinese): SHAN GUOHONG, Senior vice president of Takeda and president of Takeda China STORYLINE: Takeda Pharmaceutical, one of Japan's biggest drugmakers, is a "frequenter" at this year's China International Import Expo (CIIE) in Shanghai. Over the past six years, China has grown to be Takeda's third largest market globally. And the company's Chinese subsidiary has developed into one of the best-performing transnational pharmaceutical firms in China. SOUNDBITE (Chinese): SHAN GUOHONG, Senior vice president of Takeda and president of Takeda China "We are very pleased to be able to participate in the CIIE every year. This platform enables us to swiftly bring our global innovation achievements to China. In the future, we will continue to strengthen our coop

E

Major Chinese pharmaceutical company expands into Japan

NAGOYA, Japan - Hengrui Medicine Japan President Makoto Shimada attends a press conference in Nagoya, Japan, on July 22, 2014. Major Chinese drugmaker Jiangsu Hengrui Medicine Co. said that day it has established a Japanese subsidiary in Nagoya to sell anticancer drugs in Japan.

E

Novartis Pharma

TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.

E

Takeda to acquire Swiss drugmaker

TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa makes an announcement at a press conference in Tokyo on May 19, 2011. The largest Japanese drugmaker has signed an agreement with the shareholders of Swiss drugmaker Nycomed S/A to acquire all shares in the Swiss firm for 9.6 billion euros (about 1 trillion yen).

E

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker.

E

Drugmaker Kowa, Israel's Teva plan joint generic drug firm

TOKYO, Japan - Shlomo Yanai (L), president and chief executive officer of Israel's Teva Pharmaceutical Industries Ltd., and Yoshihiro Miwa, president of Japanese drugmaker Kowa Co., shake hands during a press conference in Tokyo on Sept. 24 at which they announced the two companies will set up a joint generic drug company in Tokyo next year.

E

Taisho, Tanabe drugmakers to merge next April

TOKYO, Japan - Akira Uehara (R), president of Japan's Taisho Pharmaceutical Co., and Toshio Tanaka, president of Tanabe Seiyaku Co., another Japanese drugmaker, shake hands during a news conference at a Tokyo hotel on Sept. 17. They announced an integration of their business operations next year in a bid to survive the intensifying race in the domestic pharmaceuticals market, the world's second largest.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi (C), president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi, president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi

The headquarters building of Japanese drugmaker Shionogi & Co. is pictured in Osaka on Dec. 27, 2021.

E

Japan halts use of 1.63 mil. Moderna vaccine doses over contamination

Japan's health ministry said Thursday foreign materials were found in some portions of unused doses of Moderna Inc.'s COVID-19 vaccine and the use of around 1.63 million doses manufactured in the same production line has been suspended as a precaution. Japanese drugmaker Takeda Pharmaceutical Co., which is in charge of sales and distribution of the vaccine in the country, said it has yet to see any reports of safety issues. Some of the 1.63 million doses distributed to 863 vaccination centers have already been used. The size of foreign substances confirmed in 39 vials is believed to be a few millimeters, with their elements being unknown. Moderna is conducting an investigation into the materials, according to the ministry and Takeda. The Ministry of Health, Labor and Welfare said foreign substances have been confirmed since Aug. 16 at eight vaccination sites in the prefectures of Ibaraki, Saitama, Tokyo, Gifu and Aichi. Takeda reported them to the ministry on Wednesday.

E

Drugmaker Kowa, Israel's Teva plan joint generic drug firm

TOKYO, Japan - Shlomo Yanai (L), president and chief executive officer of Israel's Teva Pharmaceutical Industries Ltd., and Yoshihiro Miwa, president of Japanese drugmaker Kowa Co., shake hands during a press conference in Tokyo on Sept. 24 at which they announced the two companies will set up a joint generic drug company in Tokyo next year. (Kyodo)

E

Takeda to acquire Swiss drugmaker

TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa makes an announcement at a press conference in Tokyo on May 19, 2011. The largest Japanese drugmaker has signed an agreement with the shareholders of Swiss drugmaker Nycomed S/A to acquire all shares in the Swiss firm for 9.6 billion euros (about 1 trillion yen). (Kyodo)

E

Takeda Pharmaceutical to buy Shire

Combined file photo shows the logos of Japanese drugmaker Takeda Pharmaceutical Co. (L) and Irish drugmaker Shire Plc. (Kyodo) ==Kyodo

E

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker. (Kyodo)